The U.S. Food and Drug Administration has approved the first gene therapy for a form of genetic hearing loss, marking a significant milestone in the treatment of congenital deafness. The therapy, developed by Eli Lilly and Company's Akouos division, targets mutations in the OTOF gene, which cause a type of auditory neuropathy that typically appears in early childhood.
In a statement, the FDA called the approval "groundbreaking," noting that the therapy offers the first pharmacological treatment for children with this specific genetic condition. The therapy works by delivering a functional copy of the OTOF gene directly into the inner ear via a viral vector, allowing the production of a key protein necessary for hearing.
Clinical trials showed that most children who received the treatment experienced measurable improvements in hearing, with some gaining the ability to perceive sound at near-normal levels. The approval was based on data from a phase 1/2 trial, which will continue to monitor long-term outcomes.
"This approval opens the door to a new era of genetic medicine for hearing loss," said Dr. Karen Avraham, a genetics researcher quoted in the FDA announcement. "It demonstrates that gene therapy can address one of the most common sensory deficits."
The FDA also emphasized that the therapy is for a rare form of hearing loss, affecting about 1% of children with congenital deafness. The agency recommended genetic testing to identify eligible patients.
Experts hope this success will accelerate development of gene therapies for other forms of inherited hearing loss, potentially benefiting thousands of children worldwide.